Medistim — Earnings Release 2025

Oct 24, 2025

Financial results for the third quarter and YTD September 2025 for Medistim ASA

Financial results for the third quarter and YTD September 2025 for Medistim ASA

Another strong quarter for sales revenues with 25.7 % growth, ending at MNOK 166.8 (MNOK 132.8). Record sales revenue year to date September with 25.8 % growth, ending at MNOK 517.5 (MNOK 411.5). Currency neutral sales of own products were up 29.8 % for the quarter and 28.0 % year to date September.

Strong currency neutral growth for the quarter in AMERICAS and APAC, up 35.7 % and 194 % respectively. EMEA down 11.8 %, yet up 1 % year to date September.

Third-party distributor sales in Scandinavia increased 4.4 % for the quarter and 16.2 % year to date September.

Operating profit (EBIT) grew by 27.1 % for the quarter and ended at MNOK 40.6, resulting in 24.3 % EBIT margin (MNOK 31.9, 24.0 % margin). Year to date September profit grew 46.2 % ending at a record MNOK 153.9, and 29.7 % EBIT margin (MNOK 105.2, 25.6 % margin).

Recurring sales remained high, but strong capital sales reduce recurring sales in % to 69.3% (73.7 %) compared to YTD September last year.

Solid cash position at quarter end with MNOK 157.6 after paying a dividend of NOK 6.00 per share (NOK 4.5), total MNOK 109.5 in May (MNOK 82.4). No interest-bearing